Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Grandy who wrote (539)	3/28/1997 11:12:00 PM
From: per strandberg	of 6136

John, nevapirine (Viramune) is a reverse transcriptase inhibitor, check viramune.com comparable to the wellknown AZT. These RTIs are not intended to be used as the only drug as the virus will soon mutate into a resistent form. Therefore RTIs and PIs are combined to doubly hit the virus, each drug making up for the other drug's weaknesses. With a number of RTIs and now 4 PIs approved, there are a lot of different combinations to test, especially if "cocktails" of three or more drugs are used. Viramune and Viracept may be a very good combination, these drugs are complementary, not competitors. regards, ps

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next